论文部分内容阅读
目的 探讨进展期胃癌患者围手术化疗期的细胞免疫功能及手术、化疗、免疫制剂对其影响。方法 第一阶段经手术切除的 41例胃癌患者 ,随机分为 :1.化疗组 ;2 .免化组 (5 -氟脲嘧啶联用干扰素 -alb) ;3 .单纯手术组 (对照组 )。分别于术前、术后 2周、术后 6周、术后 10周进行T细胞亚群NK细胞检测 :第二阶段对经胃癌根治术的 36例患者围手术化疗期进行了 5 -氟脲嘧啶联用干扰素 -alb的临床治疗观察。结果 进展期胃癌患者术前免疫功能存在不同程度的障碍 ,术后短期内无明显改变。结论 术后化疗可损害患者的免疫状况、联用干扰素 (IFN)可减轻化疗对免疫的损伤 (术后 6周以上尤明显 )。胃癌患者术后应继续用免疫增强剂后疗效满意
Objective To investigate the cellular immune function of patients with advanced gastric cancer during perioperative chemotherapy and the effects of surgery, chemotherapy and immunological preparations. Methods 41 patients undergoing surgical resection of the first stage of gastric cancer were randomly divided into: 1. chemotherapy group; 2. exemption group (5-fluorouracil combined with interferon-alb); 3. simple surgery group (control group) . T cell subpopulation NK cells were detected preoperatively, postoperatively 2 weeks, postoperatively 6 weeks, and postoperatively 10 weeks: In the second phase, 5-fluorourea was administered during the perioperative chemotherapy period in 36 patients undergoing radical gastrectomy. Clinical observation of pyrimidine combined with interferon-alb. RESULTS: Preoperative immune function in patients with advanced gastric cancer was impaired in different degrees and there was no significant change in the short term. Conclusions Postoperative chemotherapy can impair the patient’s immune status and interferon (IFN) can reduce the immune damage caused by chemotherapy (especially more than 6 weeks after surgery). Patients with gastric cancer should continue to be satisfied after the use of immunostimulants after surgery